Get the Stockscreener App
2.365
3.47%
-0.085
Biocardia Inc stock is traded at $2.365, with a volume of 19,844.
It is down -3.47% in the last 24 hours and up +1.94% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$2.45
Open:
$2.6
24h Volume:
19,844
Relative Volume:
0.42
Market Cap:
$11.66M
Revenue:
$468.00K
Net Income/Loss:
$-10.34M
P/E Ratio:
-0.3355
EPS:
-7.05
Net Cash Flow:
$-8.94M
1W Performance:
-4.25%
1M Performance:
+1.94%
6M Performance:
-17.02%
1Y Performance:
-64.84%
1-Day Range:
$2.32
$2.61
1-Week Range:
$2.12
$2.73
52-Week Range:
$1.625
$8.85
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
0.1978 | 409.20M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.70 | 372.90M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4356 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.26 | 96.03M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.00 | 52.42M | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
BioCardia (NASDAQ:BCDA) Upgraded at Alliance Global Partners - Defense World
BioCardia upgraded to Buy from Neutral at Alliance Global Partners - Yahoo Finance
BioCardia, Inc. Announces Acceptance of CardiAMP HF Phase 3 Study Results for Presentation at ACC 2025 - Defense World
First Patient Dosed in Phase 1 Trial of GTB-3650On January 27, 2025, GT Biopharma, Inc. (NASDAQ:GTBP) made a significant stride in its clinical development efforts with the announcement that the first patient was dosed in the Phase 1 Trial of GTB-365 - Defense World
BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions - The Manila Times
BioCardia to Present CardiAMP Phase 3 Heart Failure Trial Results at ACC 2025 - StockTitan
Comparing Apogee Therapeutics (NASDAQ:APGE) and BioCardia (NASDAQ:BCDA) - Defense World
BioCardia (FRA:6JU0) Cyclically Adjusted FCF per Share : €-23.57 (As of Sep. 2024) - GuruFocus.com
Biocardia senior vice president Edward Gillis sells $6,514 in stock - Investing.com India
Biocardia CEO Peter Altman acquires shares worth $2,060 By Investing.com - Investing.com Australia
Biocardia CEO Peter Altman acquires shares worth $2,060 - Investing.com
BioCardia’s (BCDA) “Buy” Rating Reiterated at HC Wainwright - Defense World
BioCardia stock plunges to 52-week low of $1.81 amid market challenges - Investing.com
BioCardia, Inc. (NASDAQ:BCDA) Sees Significant Decrease in Short Interest - Defense World
BioCardia's SWOT analysis: cell therapy stock faces pivotal trial phase - Investing.com India
BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family - The Manila Times
BioCardia, Inc. Announces Commercial Availability of Morph DNA Steerable Introducer Product Family - Marketscreener.com
BioCardia's SWOT analysis: cell therapy stock faces pivotal trial phase By Investing.com - Investing.com Canada
Biocardia CEO Peter Altman buys $555 in common stock By Investing.com - Investing.com Nigeria
Biocardia CEO Peter Altman buys $555 in common stock - Investing.com
Microcatheters Market Surges to USD 1.53 Billion by 2032, Propelled by 5.53% CAGRReport by S&S Insider - GlobeNewswire
BioCardia Reports Successful Consultation with Japan’s PMDA on BCDA-01 RegistrationSunnyvale, California – December 4, 2024 – BioCardia, Inc. (NASDAQ: BCDA) has recently disclosed a significant achievement regarding its lead therapeutic asset, BC - Defense World
BioCardia's SWOT analysis: cell therapy firm's stock faces clinical trial hurdles - Investing.com India
BioCardia nears Japan registration for heart failure therapy By Investing.com - Investing.com Nigeria
BioCardia nears Japan registration for heart failure therapy - Investing.com India
BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure - The Manila Times
BioCardia's Heart Failure Treatment Gains Momentum with Promising PMDA Regulatory Path in Japan - StockTitan
Biocardia CEO Peter Altman acquires $2,524 in common stock By Investing.com - Investing.com Nigeria
Biocardia CEO Peter Altman acquires $2,524 in common stock - Investing.com
BioCardia (NASDAQ:BCDA) vs. Osiris Therapeutics (OTCMKTS:OSIR) Head-To-Head Analysis - Defense World
HC Wainwright Increases Earnings Estimates for BioCardia - Defense World
BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023) - Yahoo Finance
BioCardia stock plunges to 52-week low, touches $1.93 - Investing.com India
BioCardia stock plunges to 52-week low, touches $1.93 By Investing.com - Investing.com Nigeria
BioCardia, Inc. (NASDAQ:BCDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: BioCardia announces progress in heart therapy trials By Investing.com - Investing.com UK
BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthro - GuruFocus.com
BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... - Yahoo Finance
BioCardia Reports Q3 2024 Progress and Financials - TipRanks
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - The Manila Times
BioCardia Reports 35% Net Loss Improvement, Advances CardiAMP Trial Milestone | BCDA Stock News - StockTitan
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 - The Manila Times
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Cell therapy weekly: support for commercialization of complex therapies - RegMedNet
BioCardia concludes pivotal heart failure trial - Investing.com
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure - The Manila Times
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.59% - MSN
Beating Heart Patch Market to Make Great Impact in Near Future by 2031 |BIOCARDIA, INC., Athersys, Inc - openPR
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biocardia Inc Stock (BCDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
Jan 30 '25 |
Buy |
2.38 |
239 |
569 |
107,320 |
| Altman Peter | President and CEO |
Dec 23 '24 |
Buy |
2.06 |
1,000 |
2,060 |
106,581 |
| GILLIS EDWARD M | Senior Vice President, Devices |
Dec 20 '24 |
Sale |
2.00 |
3,257 |
6,514 |
8,968 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):